Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 216, Issue -, Pages S843-S846Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix398
Keywords
human immunodeficiency virus type 1; antiviral drug therapy; reverse transcriptase; protease; integrase
Categories
Funding
- National Institutes of Health (NIH) [AI068581]
- National Institute of Allergy and Infectious Disease, NIH
- Centers for Disease Control and Prevention
Ask authors/readers for more resources
As treatment options coalesce around a smaller number of antiretroviral drugs (ARVs), data are emerging on the drug resistance mutations (DRMs) selected by the most widely used ARVs and on the impact of these DRMs on ARV susceptibility and virological response to first- and later-line treatment regimens. Recent studies have described the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitors raltegravir and elvitegravir. Several small studies have described DRMs that emerge in patients receiving dolutegravir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available